• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies.

作者信息

Pincez Thomas, Bruneau Julie, Berteloot Laureline, Piekarski Eve, Thomas Caroline, Marçais Ambroise, Trinquand Amélie, Castelle Martin, Garcelon Nicolas, Plantaz Dominique, Cheminant Morgane, Moshous Despina, Molina Thierry Jo, Hermine Olivier, Macintyre Elizabeth, Fischer Alain, Blanche Stéphane, Suarez Felipe, Neven Bénédicte

机构信息

Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris.

Pathology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris.

出版信息

Haematologica. 2020 Sep 1;105(9):e461-464. doi: 10.3324/haematol.2019.230276.

DOI:10.3324/haematol.2019.230276
PMID:33054064
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7556515/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05e8/7556515/aaab2394eaf9/105e461.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05e8/7556515/aaab2394eaf9/105e461.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05e8/7556515/aaab2394eaf9/105e461.fig1.jpg

相似文献

1
Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies.本妥昔单抗治疗原发性免疫缺陷中淋巴增殖性疾病的安全性和有效性。
Haematologica. 2020 Sep 1;105(9):e461-464. doi: 10.3324/haematol.2019.230276.
2
Brentuximab vedotin as a single agent in the treatment of a pediatric primary cutaneous CD30 lymphoproliferative disorder: A case report.本妥昔单抗单药治疗小儿原发性皮肤CD30淋巴细胞增殖性疾病：一例报告
Pediatr Blood Cancer. 2022 Jun;69(6):e29626. doi: 10.1002/pbc.29626. Epub 2022 Mar 24.
3
Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study.用维布妥昔单抗治疗的淋巴增殖性疾病患者的感染：SEIFEM多中心回顾性研究
Leuk Lymphoma. 2020 Dec;61(12):3002-3005. doi: 10.1080/10428194.2020.1786562. Epub 2020 Jul 1.
4
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.本妥昔单抗维达汀不会导致 CD30 阳性血液恶性肿瘤患者出现临床相关的 QTc 间期延长。
Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30.
5
Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.在未经移植的复发或难治性霍奇金淋巴瘤患者中应用 Brentuximab vedotin：两项 I 期研究的分析。
Oncologist. 2012;17(8):1073-80. doi: 10.1634/theoncologist.2012-0133. Epub 2012 Aug 1.
6
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.一项关于本妥昔单抗联合利妥昔单抗作为免疫抑制相关CD30+和/或EBV+淋巴瘤患者一线治疗的I/II期试验。
Leuk Lymphoma. 2021 Dec;62(14):3493-3500. doi: 10.1080/10428194.2021.1957867. Epub 2021 Aug 2.
7
Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin.在一名患有移植后淋巴细胞增生性疾病和终末期肾病的患者中，使用单药本妥昔单抗治疗使CD30阳性弥漫性大B细胞淋巴瘤完全缓解。
Leuk Lymphoma. 2015 May;56(5):1552-3. doi: 10.3109/10428194.2014.911865.
8
Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T-cell lymphoma: A FIL phase 2 study.本妥昔单抗治疗复发/难治性CD30+外周T细胞淋巴瘤：一项FIL 2期研究。
Hematol Oncol. 2022 Apr;40(2):307-309. doi: 10.1002/hon.2963. Epub 2022 Jan 19.
9
Demyelinating neuropathy and local toxicity caused by extravasated Brentuximab vedotin.
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):e626-e628. doi: 10.1111/jdv.16502. Epub 2020 May 27.
10
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.CYP3A 介导的药物-药物相互作用潜力以及 CD30 阳性血液系统恶性肿瘤患者中抗体药物偶联物 Brentuximab Vedotin 的排泄。
J Clin Pharmacol. 2013 Aug;53(8):866-77. doi: 10.1002/jcph.116. Epub 2013 Jun 10.

引用本文的文献

1
EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.EBV+ 淋巴增殖性疾病：利用 EBV 作为治疗靶点的机会。
Blood. 2022 Feb 17;139(7):983-994. doi: 10.1182/blood.2020005466.
2
Novel ZAP-70-Related Immunodeficiency Presenting with Epstein-Barr Virus Lymphoproliferative Disorder and Hemophagocytic Lymphohistiocytosis.伴有爱泼斯坦-巴尔病毒淋巴增殖性疾病和噬血细胞性淋巴组织细胞增生症的新型ZAP-70相关免疫缺陷。
Case Reports Immunol. 2021 Jun 19;2021:6587323. doi: 10.1155/2021/6587323. eCollection 2021.
3
The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers.
免疫疗法在与癌症相关的原发性免疫缺陷儿童中的应用可能性。
Biomolecules. 2020 Jul 28;10(8):1112. doi: 10.3390/biom10081112.